Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM;...
-
Projet de cuivre-or Chibougamau, Canada Faits saillants Cygnus a reçu des engagements fermes totalisant 25 M$ AU via un placement d'actions auprès d'investisseurs institutionnels et qualifiés.Le...
-
Chibougamau Copper-Gold Project, Canada Highlights Cygnus has received firm commitments totalling A$25 million via a share Placement to institutional and sophisticated investorsThe Placement was...
-
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of...
-
Brazilian Rare Earths - Sulista Rare Earth District Grows to 17 km Strike
-
Highlights Surface miner mobilised to site, with mining operations scheduled to commence in the coming weeks and first production targeted for early Q2, 2026.Updated financial cashflow modelling...
-
MCDONALD, Tenn., March 10, 2026 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTC: AMROF) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value refractory and titanium alloy...
-
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link:...
-
HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical...
-
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...